Key Points
- Tempus AI CEO Ryan Fukushima sold 20,000 shares at an average price of $50.04, generating $1.00 million. The Rule 10b5-1 transaction reduced his holdings by 13.89% to 123,945 shares.
- Tempus AI recently reported quarterly revenue of $382.49 million, up 21.6% year over year, and an adjusted loss of $0.04 per share—better than analysts’ expected loss of $0.14.
- The stock opened at $55.69, while analysts maintain a consensus “Hold” rating and an average price target of $64.92. Institutional investors own 24.22% of the company.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Ryan Fukushima sold 20,000 shares of the business's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $50.04, for a total value of $1,000,800.00. Following the sale, the chief executive officer owned 123,945 shares of the company's stock, valued at approximately $6,202,207.80. This represents a 13.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Fukushima also recently made the following trade(s):
- On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The stock was sold at an average price of $46.19, for a total value of $1,100,153.42.
- On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total transaction of $1,910,168.76.
- On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00.
- On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The shares were sold at an average price of $44.07, for a total transaction of $597,148.50.
Tempus AI Stock Performance
TEM opened at $55.69 on Wednesday. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32. The company has a market cap of $10.05 billion, a price-to-earnings ratio of -38.67 and a beta of 3.58. The company's fifty day moving average price is $51.49 and its two-hundred day moving average price is $51.68. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06.
Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to analysts' expectations of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business's revenue was up 21.6% on a year-over-year basis. During the same period last year, the company earned ($0.22) earnings per share. On average, analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.
Hedge Funds Weigh In On Tempus AI
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company's stock worth $605,772,000 after buying an additional 817,014 shares during the last quarter. ARK Investment Management LLC boosted its stake in Tempus AI by 5.3% in the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company's stock valued at $446,275,000 after acquiring an additional 381,816 shares during the last quarter. GC Wealth Management RIA LLC bought a new position in shares of Tempus AI during the 4th quarter valued at approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company's stock valued at $195,636,000 after acquiring an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. increased its stake in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company's stock worth $195,549,000 after purchasing an additional 821,490 shares during the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have commented on TEM shares. Piper Sandler decreased their price objective on Tempus AI from $58.00 to $56.00 and set a "neutral" rating for the company in a report on Tuesday, August 4th. Wolfe Research began coverage on shares of Tempus AI in a report on Tuesday, June 2nd. They set a "peer perform" rating on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of Tempus AI in a research report on Wednesday, June 17th. Lake Street Capital downgraded Tempus AI to a "hold" rating in a research note on Monday, July 20th. Finally, Guggenheim upped their target price on Tempus AI from $60.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, July 16th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $64.92.
View Our Latest Stock Analysis on TEM
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
